Dyne Therapeutics, Inc.
15.62USD
-0.1500 (-0.95%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on DYN.
Analyst Ratings
15 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 3 | 13 | 0 | 0 |
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.89▼ | -$0.77 | 1 | 1 |
| Next quarter | -$0.89▼ | -$0.79 | 0 | 1 |
| Current year | -$3.55▼ | -$3.09 | 1 | 0 |
| Next year | -$3.34▼ | -$3 | 3 | 2 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.75 | -$1.08 | -0.33 (-44.3%) |
| 2026-03-31 | -$0.78 | -$0.73 | +0.05 (+6.6%) |
| 2025-12-31 | -$0.76 | -$0.73 | +0.03 (+4.4%) |
| 2025-09-30 | -$0.85 | -$0.76 | +0.09 (+10.1%) |
100 ratings from 19 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Chardan Capital | Maintained | Buy | $38 | Sep 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $50 $32 | Sep 30, 2026 |
| Piper Sandler | Reiterated | Overweight | $47 | Sep 29, 2026 |
| Morgan Stanley | Maintained | Overweight | $45 $36 | Sep 9, 2026 |
| JP Morgan | Downgraded from Neutral | Underweight | $17 $10 | Sep 9, 2026 |
| RBC Capital | Maintained | Outperform | $35 $30 | Sep 9, 2026 |
| Baird | Maintained | Outperform | $30 $26 | Sep 9, 2026 |
| Morgan Stanley | Maintained | Overweight | $47 $45 | Jul 31, 2026 |
| RBC Capital | Maintained | Outperform | $30 $35 | Jul 30, 2026 |
| Cantor Fitzgerald | Initiated | Overweight | — | Jul 23, 2026 |
| TD Cowen | Initiated | Buy | — | Jun 26, 2026 |
| Evercore ISI Group | Maintained | Outperform | $34 $33 | May 15, 2026 |
| Bernstein | Maintained | Market Perform | $23 $24 | May 13, 2026 |
| Chardan Capital | Maintained | Buy | $38 | Mar 9, 2026 |
| Morgan Stanley | Maintained | Overweight | $50 $47 | Mar 3, 2026 |
| Chardan Capital | Maintained | Buy | $38 | Mar 3, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $60 $50 | Mar 3, 2026 |
| JP Morgan | Maintained | Neutral | $17 $16 | Jan 20, 2026 |
| Evercore ISI Group | Maintained | Outperform | $38 $36 | Dec 15, 2025 |
| Stifel | Maintained | Buy | $36 $39 | Dec 11, 2025 |
| Oppenheimer | Upgraded from Perform | Outperform | $11 $40 | Dec 10, 2025 |
| Morgan Stanley | Maintained | Overweight | $46 $50 | Dec 9, 2025 |
| Chardan Capital | Maintained | Buy | $38 | Dec 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $46 $60 | Dec 8, 2025 |
| JP Morgan | Maintained | Neutral | $18 $17 | Nov 14, 2025 |
105 filings from 16 insiders · 6 buy / 25 sell over 6m
Officers and directors of DYN, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kerr DouglasOfficer, Head of R&D and CMO | GrantStock option (right to buy) | 12.0k | — | — | Oct 20, 2026 |
| Kerr DouglasOfficer, Head of R&D and CMO | Grant | 8.0k | — | — | Oct 20, 2026 |
| Posner Brian SDirector | Buy | 2.5k | $16.00 | $40k | Oct 2, 2026 |
| Friedl-Naderer JohannaOfficer, Chief Commercial Officer | Sell | 185 | $18.88 | $3k | Sep 8, 2026 |
| Kerr DouglasOfficer, Chief Medical Officer | Sell | 1.3k | $18.88 | $24k | Sep 8, 2026 |
| Cox JohnDirector; Officer, CEO & President | Sell | 5.7k | $18.88 | $107k | Sep 8, 2026 |
| Friedl-Naderer JohannaOfficer, Chief Commercial Officer | Sell | 900 | $24.35 | $22k | Sep 4, 2026 |
| Kerr DouglasOfficer, Chief Medical Officer | Sell | 3.7k | $24.35 | $91k | Sep 4, 2026 |
| RHODES JASON PDirector | Sellindirect | 2.59M | $25.00 | $65.18M | Aug 14, 2026 |
| LUCERA ERICK J.Chief Financial Officer | Sell | 1.8k | $26.28 | $47k | Aug 13, 2026 |
| KERR DOUGLASOfficer | Sell | 1.6k | $26.28 | $41k | Aug 13, 2026 |
| COX JOHNChief Executive Officer | Sell | 5.0k | $26.28 | $131k | Aug 13, 2026 |
| FRIEDL-NADERER JOHANNAOfficer | Sell | 226 | $26.28 | $6k | Aug 13, 2026 |
| KERSTEN DIRKDirector | Sellindirect | 261.5k | $25.50 | $6.67M | Jul 27, 2026 |
| RHODES JASON PDirector | Sellindirect | 777.5k | $22.79 | $17.86M | Jul 7, 2026 |
| RHODES JASON PDirector | Sellindirect | 504.7k | $21.14 | $10.71M | Jun 29, 2026 |
| LUCERA ERICK J.Chief Financial Officer | Sell | 2.4k | $20.37 | $48k | Jun 25, 2026 |
| RHODES JASON PDirector | Sellindirect | 267.8k | $21.02 | $5.65M | Jun 25, 2026 |
| KERSTEN DIRKDirector | Sellindirect | 264.0k | $20.57 | $5.46M | Jun 23, 2026 |
| KERSTEN DIRKDirector | Sellindirect | 84.4k | $20.07 | $1.70M | Jun 18, 2026 |
No analyst notes on DYN yet.
| Buy2.00 |
| 1 mo ago | 3 | 13 | 0 | 0 | 1 | Buy2.00 |
| 2 mo ago | 3 | 13 | 1 | 0 | 0 | Buy1.88 |
| 3 mo ago | 3 | 13 | 1 | 0 | 0 | Buy1.88 |
Members whose judged calls on DYN have played out most reliably.
No settled calls on DYN yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice